Seeking Alpha

Theravance (THRX +20.6%) tops the leader board as a staff report suggests Breo — a COPD...

Theravance (THRX +20.6%) tops the leader board as a staff report suggests Breo — a COPD treatment the company is developing with GlaxoSmithKline (GSK +3.1%) — could be set for approval by the FDA which will evaluate a recommendation Wednesday. There were some questions about side effects which Citi and UBS analysts said were expected. THRX will get royalties of 15% on the first $3B in sales and 5% thereafter. 
Comments (1)
  • Michael Bryant
    , contributor
    Comments (5615) | Send Message
     
    $2.79 billion??? (THRX) is worth $2.79 billion, and it does not even have a drug on the market???? If is fails FDA approval, stock has a lot to lose.
    15 Apr 2013, 07:41 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector